Skye Bioscience (SKYE) vs Soligenix (SNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Soligenix is the larger company by market cap ($7.5 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SKYE | SNGX |
|---|---|---|
| Share price | $1.68 | $0.3466 |
| Market cap | $7.44M | $7.54M |
| 1-day change | +1.82% | -1.95% |
| EPS (TTM) | $-10.16 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.08 | $1.97 |
| 52-week low | $1.50 | $0.28 |
| Distance from 52-week high | -88.07% | -82.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +3947.62% | +298.15% |
| Average volume | 89.28K | 253.75K |
| Shares outstanding | 4.43M | 21.77M |
| Employees | 2 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Healthcare · Biotechnology · 13 employees
SKYE vs SNGX FAQ
Which is bigger, Skye Bioscience or Soligenix?
Soligenix (SNGX) is larger, with a market capitalization of $7.54M compared with $7.44M for Skye Bioscience (SKYE).
Are Skye Bioscience and Soligenix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.